Avadel Shareholders Approve Alkermes Acquisition, Paving Way for Scheme of Arrangement Completion

summarizeSummary

Avadel Pharmaceuticals shareholders overwhelmingly approved the proposed acquisition by Alkermes plc, clearing a significant hurdle for the transaction to proceed via a scheme of arrangement.

check_boxKey Events

• Acquisition Approved by Shareholders

  Shareholders overwhelmingly approved the proposed acquisition of Avadel by Alkermes plc through a scheme of arrangement, with 97.41% of votes cast at the Scheme Meeting in favor.

• EGM Resolutions Passed

  All proposals at the Extraordinary General Meeting, including the scheme approval, amendment of Articles of Association, and advisory vote on executive compensation, received strong shareholder support.

• Critical Milestone Achieved

  This approval represents a significant step towards the completion of the previously announced acquisition, removing a key condition precedent for the transaction.

auto_awesomeAnalysis

The shareholder approval of the acquisition by Alkermes plc is a critical development, signaling the near-certain completion of the transaction. This vote, conducted through both a Scheme Meeting and an Extraordinary General Meeting, confirms investor support for the deal. The approval of the scheme of arrangement and the amendment to the Articles of Association ensures that all shares will be subject to the acquisition terms, streamlining the finalization process. While the acquisition was previously announced, this definitive shareholder vote removes a major condition precedent, reducing uncertainty and paving the way for the company to be acquired. Investors should now anticipate the final steps towards the closing of the acquisition.